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136Differential Features between Chronic Skin
Inflammatory Diseases Revealed in
Skin-Humanized Psoriasis and Atopic
Dermatitis Mouse Models
Marta Carretero1,2,3, Sara Guerrero-Aspizua2,3,4, Nuria Illera1,2,3, Victoria Galvez1,2,3,
Manuel Navarro5, Francisco Garcı´a-Garcı´a6, Joaquin Dopazo2,6,7, Jose Luis Jorcano1,4,
Fernando Larcher1,2,3 and Marcela del Rio1,2,3,4Psoriasis and atopic dermatitis are chronic and relapsing inflammatory diseases of the skin affecting a large
number of patients worldwide. Psoriasis is characterized by a T helper type 1 and/or T helper type 17 immu-
nological response, whereas acute atopic dermatitis lesions exhibit T helper type 2-dominant inflammation.
Current single gene and signaling pathways-based models of inflammatory skin diseases are incomplete.
Previous work allowed us to model psoriasis in skin-humanized mice through proper combinations of in-
flammatory cell components and disruption of barrier function. Herein, we describe and characterize an animal
model for atopic dermatitis using similar bioengineered-based approaches, by intradermal injection of human
T helper type 2 lymphocytes in regenerated human skin after partial removal of stratum corneum. In this work,
we have extensively compared this model with the previous and an improved version of the psoriasis model, in
which T helper type 1 and/or T helper type 17 lymphocytes replace exogenous cytokines. Comparative
expression analyses revealed marked differences in specific epidermal proliferation and differentiation markers
and immune-related molecules, including antimicrobial peptides. Likewise, the composition of the dermal
inflammatory infiltrate presented important differences. The availability of accurate and reliable animal models
for these diseases will contribute to the understanding of the pathogenesis and provide valuable tools for drug
development and testing.
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Atopic dermatitis (AD) and psoriasis (PS) are themost common
chronic inflammatory diseases of the skin. Both pathologies
are associated with a skin barrier defect that correlates in de-
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and gene expression patterns (Segre, 2006). AD is character-
ized by an immunological imbalance leading to the predom-
inance of T helper type 2 (Th2) cells in acute skin lesions,
whereas T helper type 1 (Th1) and T helper type 17 (Th17)
constitute the main lymphocyte subpopulations found in
psoriatic plaques. During chronification of atopic skin disease,
the immunologic response switches toward the Th1 type. The
involvement of Th17 and/or Th22 lymphocyte subpopulations
in AD disease has also been discussed (Koga et al., 2008;
Nograles et al., 2009). For both inflammatory skin diseases,
several animal models have been developed, most of them
based on transgenic and knockout mice (Danilenko, 2008;
Gudjonsson et al., 2007; Jin et al., 2009). However, differ-
ences between mouse and human skin architecture and im-
mune function reveal major limitations in the use of these
animal models for drug discovery and pathophysiological
studies.Moreover,manipulating a single gene usually does not
recapitulate the full phenotype of such complex inflammatory
skin diseases. In this regard, the xenotransplantation model
recreates more accurately the microenvironment found in
human skin diseases (Boehncke et al., 1996;Wrone-Smith and
Nickoloff, 1996). Nonetheless, a major drawback to the use of
xenotransplantation models is the limited number of animals
that can be obtained harboring large and homogeneous
skin samples. In our laboratory, we have developed authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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engineered skin approach that overcomes themain limitations
of the above-mentioned animal models, such as heterogeneity
and availability of human biopsy samples (Guerrero-Aspizua
et al., 2010). Using this technology, we have demonstrated
that a healthy normal human skin regenerated in immunode-
ficient mice might develop a psoriasiform phenotype in the
presence of adequate signals provided byawounding stimulus
and the appropriate cytokines. These cytokines were provided
either by in vitro-polarized specific lymphocyte sub-
populations (Th1) obtained from unrelated healthy donors
or produced in their recombinant form in the case of IL17
and IL22 Th17 cytokines. The versatility of the system
prompted us to investigate the possibility of generating a
skin-humanized mouse model for a typical Th2-mediated skin
disease, such as AD. In this work, we have demonstrated
by histological, immunohistochemical, and quantitative re-
verse transcriptase in real time analyses that the injection
of in vitro-differentiated Th2 lymphocytes in regenerated
human skin elicited an AD phenotype that closely resembles
the acute human AD condition. Moreover, a comparative
analysis with PS biopsies as well as with the skin-humanized
PS model revealed the major differential traits between these
two prevalent cutaneous inflammatory diseases.
RESULTS
Generation of PS and AD skin-humanized mouse models
We took advantage of the previously characterized skin-
humanized mouse model for PS (Carretero et al., 2013;
Guerrero-Aspizua et al., 2010). In those studies, we demon-
strated that normal human skin regenerated by bioengineered-
based approaches onto the back of immunodeficient mice
developed a psoriasiform phenotype after the injection of
in vitro-differentiated Th1 lymphocytes together with recom-
binant IL22 and IL17 cytokines and removal of moderate
stratum corneum through tape stripping (TS). Herein, we
present an improved animal model for PS in which differen-
tiated Th17 and/or Th1 lymphocytes produce the cytokines
(IFNg, IL22, and IL17) that have been shown to be relevant for
the cutaneous phenotype. In addition, and following the same
experimental approach, a skin-humanized mouse model for
AD has been developed by introducing in vitro-differentiated
Th2 lymphocytes (Figure 1a). We used established protocols
for in vitro activation and cytokine-directed polarization of
human naive CD4þ T cells isolated from cord blood to obtain
the specific Th1, Th2, and Th17 lymphocyte subpopulations
(de la Fuente et al., 2014; Ghoreschi et al., 2010) (see the
Materials and Methods section, and Supplementary Methods
online). The expression of specific transcription factors and
cytokines was evaluated by flow cytometry in each case
(Supplementary Figure S1 online). The transcription factor T-
bet is preferentially expressed by Th1 cells (Szabo et al., 2000).
By day 7 of Th1 differentiation, a large percentage of cells
expressed both IFNg and the T-bet transcription factor
(20e40% of positive cells depending on donor) reaching a
maximum by day 14 of differentiation (60e80%),
(Supplementary Figure S1, left panels). Most of them also
expressed TNFa (data not shown). A high percentage of Th2
cells (40e50%) expressed IL4 together with the specific
GATA-3 transcription factor (Zheng and Flavell, 1997) by day7 of differentiation. By day 14, GATA-3 and IL4 expression is
upregulated and then maintained until day 21 of differentia-
tion (50e60%) (Supplementary Figure S1, central panels). IL5
and IL13 expression was also detected at days 14 and 21 of
Th2 differentiation (data not shown). Differentiation of human
Th17 cells yielded a high percentage of cells (approximately
70%) expressing the RORgt transcription factor (Ivanov et al.,
2006) between days 14 and 21 of differentiation. Most cells
also expressed IL22, IFNg, and TNFa. IL17 expression was
also detected at day 14 of differentiation (Supplementary
Figure S1, right panels and data not shown). This cell popu-
lation showed similar characteristics to a previously described
in vitro-derived Th17 and/or Th1 cell subpopulation (Wilson
et al., 2007) that was demonstrated to secrete both IL17 and
IFNg among other factors. The presence of these cells has also
been demonstrated in elevated numbers in inflamed tissues
(Boniface et al., 2010). For this reason we have referred to this
in vitro-derived lymphocyte subpopulation as Th17 and/or
Th1 throughout this report.
Histological characterization of the PS- and AD-like
phenotype in the humanized mouse models
Histological analyses showed that injection of either Th1
lymphocytes together with recombinant IL17 and IL22 cyto-
kines or in vitro-differentiated Th17 and/or Th1 cells (PS
models) induced the typical epidermal changes associated
with PS when TS was applied, including epidermal hyperpla-
sia, elongation, and fusion of rete ridges, parakeratosis, and
partial loss of the granular layer (Guerrero-Aspizua et al., 2010;
Figure 1b). The dermis was characterized by an influx of in-
flammatory cells and increased vascularity, with the presence
of dilated capillaries. Histological examination of regenerated
human skin in which human Th2 lymphocytes were injected
together with the application of TS (AD model) revealed
moderate thickening of the epidermis as compared with con-
trol samples, with no obvious changes in the differentiation
process. At the dermal level, the AD model also showed
increased numbers of inflammatory cells and enhanced
angiogenic response (Figure 1b). All the histological features
closely resemble those found in human skin biopsies from
patients with PS and AD (Supplementary Figure S2 online).
Differential epidermal hallmarks between the PS and AD
skin-humanized mouse models
We evaluated the expression of keratinocyte proteins that are
present in normal human skin but whose expression was
shown to be altered in PS and AD. The immunohistochem-
istry (IHC) analysis of involucrin (IVL) showed similar
increased expression in samples of both humanized AD
(Th2 þ TS) and PS (Th17 and/or Th1 þ TS and Th1 þ IL17 þ
IL22 þ TS) models, as compared with control samples
(phosphate buffered saline 1 þ TS) (Figure 2 and
Supplementary Table S1 online). In contrast, focal down-
regulation of keratin 1 (KRT1) was observed in all samples
corresponding to the humanized model for AD and PS
(Figure 2 and Supplementary Table S1), whereas patchy
expression of loricrin (LOR) was observed exclusively in the
PS model (Figure 2 and Supplementary Table S1), corre-
sponding to areas where a lack of a well-developed granular
layer was evident (Figure 1b). In contrast, no discontinuity of
LOR expression was observed in any of the samples in whichwww.jidonline.org 137
Figure 1. PS and AD skin-humanized mouse models. (a) Schematic diagram of the experimental design for the generation of skin-humanized mouse models for
PS and AD. (b) H&E staining was performed on formalin-fixed paraffin-embedded sections of human skin grafts treated with PBS1 or those injected
intradermally with in vitro-differentiated Th17 and/or Th1 or Th2 lymphocyte subpopulations. Tape stripping (TS) was applied where indicated. Scale bar ¼ 100
mm. Images are representative of two independent experiments with two to three mice per group. AD, atopic dermatitis; H&E, hematoxylin and eosin; PBS,
phosphate buffered saline; PS, psoriasis; Th1, T helper type 1; Th2, T helper type 2; Th17, T helper type 17.
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Figure 2. Immunohistochemical
analysis of epidermal differentiation
markers in the PS and AD skin-
humanized mouse models.
Consecutive formalin-fixed paraffin-
embedded sections used in Figure 1b
were stained for involucrin, KRT1, and
loricrin differentiation markers. Scale
bar ¼ 50 mm. Images are
representative of two independent
experiments with two to three mice
per group. AD, atopic dermatitis; PS,
psoriasis.
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expression of other markers associated with hyper-
proliferation, such as Ki-67 and KRT17, was also evaluated.
Increased Ki-67-positive keratinocyte nuclei as compared
with controls were found in both PS and AD models. How-
ever, a high proportion of positive cells showed suprabasal
localization in the PS model although mainly confined to the
basal/parabasal compartment in AD. Suprabasal KRT17
expression was specifically induced in hyperproliferative
samples corresponding to the humanized model for PS
(Figure 3). Another characteristic of AD lesions is the pres-
ence of apoptotic cells in the epidermis (Trautmann et al.,2001). Increased numbers of TUNEL-positive cells were
also identified in the skin-humanized mouse model for AD as
compared with the PS model and control samples
(Supplementary Figure S3 online).
To validate the changes observed in the PS and AD models,
a comparative marker expression analysis was performed,
including biopsies from patients with PS and AD. The
comparative IHC analyses for the epidermal markers
revealed similar staining patterns to those observed in human
plaque PS and AD lesions corresponding to the acute and/or
subacute stages. A significant alteration in the epidermal
differentiation pattern (IVL, KRT1, and LOR staining) waswww.jidonline.org 139
Figure 3. Immunohistochemical analysis of epidermal proliferation markers
in the PS and AD skin-humanized mouse models. (a) Consecutive formalin-
fixed paraffin-embedded sections used in Figures 1b and 2 were stained for
Ki-67 and KRT17. Arrowheads show Ki-67-positive proliferating cells. Scale
bar ¼ 50 mm. Images are representative of two independent experiments with
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normal human skin. KRT17 and psoriasin (S100A7) were
highly expressed in PS samples as compared with normal
human skin and AD (Supplementary Figure S2a).
Thymic stromal lymphopoietin (TSLP) is a type I cytokine
that has been shown to be elevated in the lesional skin of
human patients with AD, and it promotes Th2 responses
(Soumelis et al., 2002). It has been previously shown that
skin-specific overexpression of TSLP resulted in an AD-like
phenotype in mice (Yoo et al., 2005). We have explored
the expression of this cytokine in our skin-humanized mouse
models. IHC analysis revealed an increased expression of
TSLP in tissue sections of the AD model as compared with the
PS model and control samples (Supplementary Figure S4a
online). It has been previously shown that IL-1b, TNFa, IL-
4, and IL-13 cytokines, found at high levels in the lesional
skin of patients with AD, can synergize to induce TSLP
expression in keratinocytes (Bogiatzi et al., 2007). Quanti-
tative mRNA expression analysis confirmed these results. We
found high levels of expression of this cytokine exclusively in
those samples with detectable human IL4 mRNA expression
(Supplementary Figure S4b). TSLP expression was also found
to be increased in human biopsy samples corresponding to
patients with AD as compared with PS or normal human skin
(Supplementary Figure S2c).
The immune defense barrier function of the skin is
enhanced by the inducible expression of antimicrobial pep-
tides and proteins (AMPs). This barrier is rapidly activated
when skin integrity is compromised after injury or infection.
Difference in AMP expression between PS and AD appears to
be an important factor in the susceptibility of both disorders
to secondary infection (de Jongh et al. 2005; Ong et al. 2002).
In this work, we have observed a clear upregulation of
psoriasin (S100A7) expression in samples corresponding to
both skin-humanized mouse models, although higher levels
of expression were observed in the PS model (Figure 4 and
Supplementary Table S1). The induction of psoriasin expres-
sion correlated with the observed increase in epidermal
proliferation (Figure 3). We have also observed a clear
upregulation of calprotectin (S100A8/9) expression exclu-
sively in PS skin-humanized mouse model samples involving
all layers of epidermis, except for the basal cell layer (Figure 4
and Supplementary Table 1). Both Th2 and Th17 and/or Th1
appeared to slightly induce elafin (proliferative index 3, P13)
expression in the most upper layers of the epidermis. In the
presence of a mild barrier disruption by TS, Th17 and/or Th1
but not Th2 cells, increased elafin expression that is localized
in spinous layers of the epidermis. Th1 þ IL17 þ IL22 þ TS
was the condition that yielded the highest levels of elafin
expression, with more epidermal layers affected (Figure 4 andtwo to three mice per group. (b) The proliferation index (PI) was determined as
the percentage Ki-67 staining of the epidermis either in the basal layer (basal
PI) or suprabasal layers (suprabasal PI), and both are referred to as the number
of positive stained cells per 100 total basal cells. At least two nonoverlapping
high-power fields (HPF) were quantified (1 field ¼ 0.379 mm2), and three to
five samples per experimental group of animals were included. Data
represent mean  SEM (*P < 0.05 when compared with the PBS1 þ TS
control group according to a t-test). AD, atopic dermatitis; PBS, phosphate
buffered saline; PS, psoriasis; TS, tape stripping.
=
Figure 4. Immunohistochemical analysis of epidermal AMP expression in the PS and AD skin-humanized mouse models. Consecutive formalin-fixed paraffin-
embedded sections used in Figures 1b, 2, and 3 were stained for psoriasin (S100A7), calprotectin (S100A8/9), elafin (PI3), and secretory leukocyte protease
inhibitor (SLPI). Scale bar ¼ 50 mm. Images are representative of two independent experiments with two to three mice per group. AD, atopic dermatitis; AMP,
antimicrobial peptide; PS, psoriasis; TS, tape stripping.
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secretory leukocyte protease inhibitor was detected by IHC
exclusively in the upper layers of epidermis of the PS model
(Figure 4 and Supplementary Table S1). We have also
observed higher expression levels of human beta defensin-2
and LL-37 AMP expression in samples corresponding to the
PS as compared with the AD skin-humanized mouse model(Supplementary Figure S5 online). As observed with the
epidermal differentiation markers, our models recapitulate
the patient conditions because epidermal expression of cal-
protectin (S100A8/9), elafin (proliferative index 3, PI3), and
SLPI was also highly induced in human skin biopsies
from patients with PS as compared with those with AD
(Supplementary Figure S2).www.jidonline.org 141
Figure 5. Composition of dermal
inflammatory infiltrate in the PS and
AD skin-humanized mouse models.
(a) The injected human T cells in the
tissue were localized by using an
antibody against CD3-ε T-cell specific
antigen. The composition of the
inflammatory infiltrate was analyzed by
using specific stains and IHC of
consecutive formalin-fixed paraffin-
embedded tissue sections. Mast cells
were detected using toluidine blue
staining. Anti-IL8 was used to detect
dermal positive mast cells. Cells of the
granulocyte series were detected using
specific antibodies against MPO and
EMBP. The arrowheads indicate positive
cell staining. Scale bar¼ 50 mm. Images
are representative of two independent
experiments with two to three mice per
group. (b) The quantification of
inflammatory infiltrate in the PS and AD
skin-humanized mouse models. The
average number of positive-stained
inflammatory cells were quantified by
examining two to eight randomly
selected high-power fields (HPF) per
sample (1 field¼ 0.093mm2) from three
to five tissue sections for each
experimental group of animals. The
numberofpositivecellswasexpressedas
cells permm2 (mean SEM). *P< 0.05,
**P< 0.01.AD,atopic dermatitis; EMBP,
eosinophil major basic protein; IHC,
immunohistochemistry; MPO,
myeloperoxidase; PS, psoriasis.
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142Dermal characterization of PS and AD skin-humanized
mouse models
To demonstrate the persistence of the injected human
Th1, Th17, and Th2 cells in samples obtained from our
skin-humanized mouse model, we used a human-specific
anti-hCD3ε antibody. T cells were localized by IHC near
the dermo-epidermal junction and even infiltrating theJournal of Investigative Dermatology (2016), Volume 136epidermis in some sample sections (Figure 5). Mast cells have
been shown to be important players in the pathogenesis of PS
and AD (Fischer et al., 2006). In this work, we have observed
the increased number of IL8þ mast cells by toluidine blue
staining and IHC in samples corresponding to the skin-
humanized mouse model for PS and AD (Figure 5).
Increased numbers of myeloperoxidase-positive cells were
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compared with the AD model. In contrast, higher numbers of
eosinophils were detected in samples corresponding to the
AD model by using a specific anti-eosinophil major basic
protein antibody that reacts with the eosinophil major basic
protein, a constituent of the crystalline core of the eosinophil
granule (Figure 5). Augmented angiogenic reaction and
increased vascular permeability are also key features of many
chronic inflammatory diseases, such as PS and AD. The
expression of adhesion molecules on activated blood
vascular endothelial cells enables extravasation of inflam-
matory cells (Zgraggen et al., 2013). In this context, ICAM-1
marker expression for endothelial activation has also been
investigated. The presence of dilated capillaries in the dermis
of both PS and AD skin-humanized mouse models was
assessed by CD31 staining that correlated with an enhanced
ICAM-1 expression in dermal vessels in both models
(Supplementary Figure S6 online).
DISCUSSION
An intact barrier function is required to protect the body from
a wide variety of external insults. A defective skin barrier is a
key feature of chronic inflammatory skin diseases. Several
reports have demonstrated an altered expression of genes
belonging to the epidermal differentiation complex in sam-
ples obtained from the lesional skin of patients with PS and
AD compared with healthy donors or uninvolved skin.
Consistently, we have observed increased IVL expression in
the experimental humanized mouse model for PS that is in
agreement with results obtained by different laboratories us-
ing microarray analyses on mRNA from patients with chronic
plaque PS and AD (de Jongh et al., 2005; Suarez-Farinas
et al., 2010). Altered patterns of LOR expression were
detected in both the skin-humanized mouse models for PS
and AD. We have previously reported the presence of focal
areas of inhibition of LOR expression in the skin-humanized
mouse model for PS corresponding to areas where the gran-
ular layer was absent, and that this inhibition is mainly due to
the presence of the Th17-derived IL22 cytokine (Guerrero-
Aspizua et al., 2010). In this work, we have observed that
LOR expression was induced in the skin-humanized mouse
model for AD, concomitantly with an increased thickness in
the granular layer found in these samples. With respect to
epidermal proliferation markers, it has been shown that the
induction of KRT17 is specific for the inflammatory reactions
associated with high levels of signal transducer and activator
of transcription 1-activating cytokines, such as IFNg, IL6, and
leukemia inhibitory factor (Komine et al., 1996). It has also
been described that IL22, IL17A, and IFNg can synergistically
induce KRT17 expression in keratinocytes (Zhang et al.,
2012). Other cytokines working through signal transducer
and activator of transcription 1-independent pathways, such
as IL3, IL4, IL10, and granulocyte macrophage colony stim-
ulating factor, were shown to have no effect on KRT17
expression (Komine et al., 1996). In agreement with these
reports, we have observed a clear induction in KRT17
expression exclusively in the skin-humanized mouse model
for PS. We have also observed increased numbers of Ki-67-
positive nuclei by IHC in the skin-humanized mouse modelfor PS as compared with AD, especially in suprabasal layers
of the epidermis.
In addition to structural proteins, multiple AMPs contribute
to the skin barrier function, playing a crucial role in defense.
Among them, cathelicidins, b-defensins, and S100 proteins
are part of this antimicrobial skin barrier. It has been
demonstrated that IL22, together with IL17, synergistically
increases the expression of skin AMPs, including S100A7
(psoriasin), S100A8/9 (calprotectin), and human b-defensin-2
(Liang et al., 2006). The increased susceptibility of AD skin to
microorganisms has been explained as the result of local
upregulation of Th2 cytokines, such as IL4 and IL13, that have
been shown to inhibit AMP expression (Ong et al., 2002). In
this work, we have demonstrated that a large number of
AMPs are highly induced in the skin-humanized mouse
model for PS as compared with the AD model, thus con-
firming previous studies (de Jongh et al., 2005).
Accumulating evidence supports the notion that skin bar-
rier dysfunction plays a prominent role in the development
and perpetuation of PS and AD inflammatory diseases of the
skin. In fact, the use of emollients to replace ceramide con-
tent and to achieve normalized AMP expression has been
shown to be effective in restoring epidermal function (Elias
et al., 2008; Rodriguez-Martin et al., 2011). In this regard,
we have previously demonstrated that normalization in hu-
man beta defensin-2 expression in the epidermis of the skin-
humanized mouse model for PS by topical application of
DEFB4-siRNA-containing SECosomes resulted in the recov-
ery of TGM activity, filaggrin expression, and stratum cor-
neum appearance, as well as a reduction in the number and
size of blood vessels in the dermal compartment (Bracke
et al., 2014).
Modeling a complex disease such as AD is a challenge, as
it cannot be envisioned as a unique clinical entity. Lesions of
AD may be classified as acute, subacute, or chronic ac-
cording to the clinical findings, and differential histological
hallmarks of each stage of the disease can be distinguished in
skin lesions. Chronic lichenified lesions of AD share some of
the histological features of PS, with marked epidermal hy-
perplasia, elongation of the rete ridges, and prominent hy-
perkeratosis. Additional variability is found depending on the
patient’s age, severity of inflammation, chronic scratching,
and the presence of secondary infections. Lesions in various
stages often exist in the same individual. Although a Th2
signal predominates the acute phase, chronic lesions are
characterized by a Th2 to Th1 switch response, with elevated
expression of IFNg, IL12, and GM-CSF. The skin-humanized
mouse model for AD presented herein more likely reflects the
acute condition, as no Th1 lymphocytes are present in
these samples. The comparative histological and immuno-
histochemical analyses in human skin biopsies correspond-
ing to the acute and/or subacute phenotype support this
assumption (Supplementary Figure S2). In addition, two
distinct forms of AD can be distinguished clinically. The
intrinsic variant (15e45% of patients) is characterized by a
lack of IgE-mediated sensitization, whereas the extrinsic type
of AD occurs in the majority of affected children and is
associated with the presence of allergen specific IgE against
inhalant and/or nutritive allergens. Early onset of this type ofwww.jidonline.org 143
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144AD constitutes a known risk factor for the subsequent
development of other atopic diseases. Our present skin-
humanized mouse model for AD does not include specific
antigen-sensitized T-lymphocytes. However, it has also been
demonstrated that a high total-serum IgE level is also a strong
risk factor for AD in children and is associated with persistent
eczema in adults (Zheng et al., 2011). Although we were able
to detect human T-lymphocytes in lymph nodes from animals
that were intradermally injected with Th2 cells (AD model), it
seems that the low percentage of human T cells detected
(0.186e0.375%), although significant, is not sufficient to
drive a B-cell response with detectable serum IgE production
(data not shown).
Although a limitation exists, as the skin-humanized
mouse model for AD presented here does not cover all
the clinical manifestations of the disease, it offers unique
possibilities to dissect the contribution of the different
lymphocyte subpopulations and/or cytokines to the cuta-
neous phenotype. Accepted mouse models for AD include
those induced by epicutaneous application of sensitizers,
transgenic and knockout mice, and spontaneous mouse
models of AD (Jin et al., 2009). This AD animal model
developed in a humanized context is to our knowledge
previously unreported. Skin-humanized models for in-
flammatory diseases emerge as powerful tools to study the
mechanisms underlying the pathogenesis of these dis-
eases. These models offer unique possibilities to study the
specific phenotypic alterations of the epithelium that
occur in the presence of either Th17 and/or Th1 or Th2
lymphocyte subsets in a humanized context. These studies
will be of interest to unravel the mechanisms involved in
different stages of both pathologies. Although the gener-
ation of skin-humanized mouse models for inflammatory
diseases is rather technically complex, the possibility of
obtaining a large number of animals with the disease
phenotype starting from healthy donor cellular compo-
nents represents a main advantage over other current
animal models.
MATERIALS AND METHODS
Lymphocyte isolation and T-cell expansion
Human umbilical cord blood samples from normal full-term de-
liveries were obtained from the Centro de Transfusio´n de la Comu-
nidad de Madrid, and in all cases written informed consent was
obtained. Primary human T cells were isolated from umbilical cord
blood by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) gradient
centrifugation and negative immunomagnetic selection using the
Naive CD4þ T-cell Isolation Kit II (Miltenyi Biotec, Auburn, CA). For
Th1 differentiation, cells (2  106/ml) were activated in anti-CD3
plus anti-CD28 (clones HIT3a and CD28.2; BD PharMingen,
Franklin Lakes, NJ) coated plates. Then, cells were cultured for 24
hours in the presence of 40 U/ml hIL2 (Roche Applied Science,
Indianapolis, IN) and for additional 6e20 days in the presence of 5
mg/ml blocking anti-IL4 mAb and 2.5 ng/ml hIL12 (R&D Systems,
Minneapolis, MN). For Th17 and/or Th1 cell differentiation, isolated
naı¨ve CD4þ T cells were cultured for 5 days in anti-CD3 plus anti-
CD28-coated plates in the presence of 5 mg/ml blocking anti-IL4 and
anti-IFNg antibodies (R&D Systems), 50 ng/ml hIL-6, and 10 ng/ml
IL1b (Miltenyi Biotec). Then, the cells were washed and incubated in
media supplemented with 20 U/ml hIL-2 and 20 ng/ml IL23 (R&DJournal of Investigative Dermatology (2016), Volume 136Systems) for additional 2e16 days. For Th2 differentiation, the cells
were cultured for 7e21 days in anti-CD3 plus anti-CD28-coated
plates in the presence of 10 U/ml IL2, 10 ng/ml IL4 (Miltenyi Bio-
tec), 2 mg/ml blocking anti-IL12 (R&D Systems), and 5 mg/ml
blocking anti-IFNg antibodies.
Bioengineered human skin equivalents and grafting
Primary human keratinocytes and dermal fibroblasts were isolated
by enzymatic digestion from donor skin biopsies that were obtained
from Spanish Blood and Tissue Bank (Centro Comunitario de Sangre
y Tejidos, Oviedo, Spain), and in all cases written informed consent
has been obtained. This study was conducted according to the
Declaration of Helsinki Principles. Primary keratinocytes were
cultured on a feeder layer of lethally irradiated (X-ray; 50 Gy) 3T3-J2
cells as previously described (Guerrero-Aspizua et al., 2010). Pri-
mary fibroblasts were cultured in DMEM containing 10% fetal
bovine serum at 37 C in a humid atmosphere containing 5% CO2.
The bioengineered human skin equivalent is based on the use of
fibrin containing live fibroblasts as a dermal component and was
prepared as previously described (Guerrero-Aspizua et al., 2010).
For the grafting protocol immunodeficient Rj: NMRI—Foxn1nu
(NMRI nu) mice (6e8 weeks old) were used (Elevage Janvier, Le
Genest Saint Isle, France). Mice were aseptically cleansed and
grafted as previously described (Carretero et al., 2013). They were
housed for the duration of the experiment at the CIEMAT Laboratory
Animal Facility (European Registration number ES280790000183) in
pathogen-free conditions using microisolators, individually venti-
lated cages of type IIL, at a maximum of six mice per cage, with 25
air cage changes per hour and heat-treated softwood pellets as
bedding. All experimental procedures were carried out according to
the European and Spanish laws and were in keeping with regulations
on the protection and use of animals in scientific research. All
procedures were approved by the Institutional Animal Care and Use
Committee according to all legal regulations, and biosafety and
bioethics guidelines.
Intradermal injection of T-lymphocyte subpopulations and
recombinant cytokines
Recombinant cytokines (200 ng) and/or in vitro-derived T-lympho-
cyte subpopulations (5  105) were inoculated by intradermal in-
jection into the stable engrafted human skin every other day for 2
weeks as previously described (Guerrero-Aspizua et al., 2010).
Where indicated, the same skin area was tape-stripped 15 times
before injection. Mice were killed by carbon dioxide asphyxiation 2
days after the last intradermal injection, and skin biopsies were taken
and processed for histological and IHC analysis.
Histology and IHC
Formalin-fixed paraffin sections (4e6 mm) were used for standard
histological and IHC analyses. To determine tissue architecture,
sections were stained with hematoxylin and eosin (Gill 2 Hema-
toxylin and Eosin Y alcoholic; Thermo Shandon, Altrincham, UK)
following a standard procedure. For immunoperoxidase staining, the
following primary antibodies were used: anti-Elafin/Skalp (Abcam,
Cambridge, UK), anti-IL8 (Lifespan Biosciences, Seattle, WA), anti-
IVL (clone SY5; Sigma-Aldrich), anti-Ki-67 (clone SP6, Neo-
markers, Fremont, CA), anti-KRT1 and anti-KRT17 (Sigma-Aldrich),
anti-LOR (Babco, Richmond, CA), anti-macrophage L1 protein cal-
protectin (Abcam), anti-myeloperoxidase (HyCult Biotech, Uden,
the Netherlands), anti-psoriasin/HID5/S100A7 (Imgenex, San Diego,
CA), anti-SLPI (Sigma-Aldrich), and antieeosinophil major basic
M Carretero et al.
Skin-Humanized Model for Inflammatory Diseasesprotein (S-16; Santa Cruz Biotechnology, Santa Clara, CA). For
alkaline phosphatase detection, rabbit antihuman anti-TSLP (Life-
Span BioSciences) and anti-hCD3ε antibody (Dako, Glostrup,
Denmark) were used. Mast cells were detected by toluidine blue
staining of formalin-fixed samples.
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